Northstar All themes →
Home / Themes / Healthcare

Dental Tech

Digital Health & Med-TechHealthcare Updated 2026-09-04

Clear aligners and digital dentistry have matured into a genuinely competitive, multi-billion-dollar category since Align's key patents expired in 2017 — Envista, Straumann, Dentsply Sirona and Chinese entrants like Angelalign have all built credible platforms, but category growth has slowed to single digits even as the underlying market CAGR headline stays much higher.

📈 What changed: Straumann Group posted 7.8% organic H1 2026 revenue growth and raised its 2026 profitability guidance, with ClearCorrect continuing fast growth — a sharper contrast to Align's Q2…

The Northstar view

Primary State
Genuinely Competitive, Post-Patent-Expiration ActiveMultiple credible platforms now compete against Align's incumbency
Near-Term Value
Recurring Device & Consumable Revenue ActiveAlign $1.06B Q2 2026 revenue (+4.3% YoY); Dentsply Sirona $898M Q2 2026 net sales
Main Risk
Slowing Category Growth WatchAlign Q2 2026 revenue +4.3% YoY; Straumann (+7.8%) and Envista (+5.0%) outgrowing it
Conviction
Medium StableMature category; execution and AI differentiation matter more than category growth
Next Trigger
AI-enabled diagnostic feature adoption 2026Whether Smart View-Detect-style tools become a genuine differentiator

Six-indicator scorecard

IndicatorScoreReading
Maturity
higher is better · high confidence
82/100
A mature, scaled category where patent expiration since 2017 has finally produced genuine multi-vendor competition against Align's incumbency.
Evidence Strength
higher is better · high confidence
85/100
SEC filings and multiple independent market-research houses corroborate the category's scale and growth trajectory.
Commercial Proximity
higher is better · high confidence
71/100
Real, mature recurring revenue, but growth has slowed to single digits as competition intensifies post-patent-expiration.
Capital & Policy Support
higher is better · low confidence
26/100
Expanding insurance reimbursement in select markets matters more than any coordinated public strategy.
Crowding Risk
lower is better · high confidence
33/100
Align's post-2021 multiple has compressed meaningfully as patent-expiration competition intensified — a moderated, not extreme, crowding picture.
Reflexivity Risk
lower is better · high confidence
29/100
Earnings-grounded and largely self-funding, with competitive-share narratives occasionally driving re-ratings.

Every indicator score is computed by the Northstar engine from analyst-set ordinal bands — never hand-written, never stored.

Related tickers

ALGNSTMN.SWNVST6699.HKXRAYDDDHSICPDCOCLSOLV

See the full Dental Tech briefing

The public page is the summary (backed by 15 cited sources). Full briefing — company map, catalysts, native signals and sources — is inside the app.

Open in the appStart free →

The Northstar Signal — what moved across all 350+ themes and why, in your inbox. Free, no spam, one-click unsubscribe.

More in Healthcare

GLP-1 & the Metabolic Health RevolutionGLP-1 receptor agonists have become the fastest-adopted drug class in pharmaceutical hist…Longevity Biotech & the Biology of AgeingLongevity biotech is transitioning from high-concept science to early-stage clinical vali…Precision MedicineGenomic, molecular and AI-driven diagnostics are converging into a single treatment-selec…Diagnostic GenomicsLiquid biopsy and NGS-based screening are moving cancer detection upstream of diagnosis —…Gene EditingGene editing has crossed from proof-of-concept to a genuine, if still narrow, commercial…Cell TherapyCell therapy has moved past proof-of-concept into a genuine multi-billion-dollar commerci…mRNA TherapeuticsThe mRNA platform that COVID built is now being redirected at oncology and rare disease,…AI Drug DiscoveryAI drug discovery has attracted more capital in 2026 than any biotech subsector since imm…